Connect Biopharma (CNTB) vs Mereo BioPharma Group (MREO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Connect Biopharma (CNTB) has outperformed Mereo BioPharma Group (MREO) over the past year, losing 51.6% versus a loss of 80.9%. Over five years, MREO leads with a -82.8% price change compared with -94.9% for CNTB. Connect Biopharma is the larger company by market cap ($57.9 million vs $57.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTB | MREO |
|---|---|---|
| Share price | $0.9193 | $0.3608 |
| Market cap | $57.89M | $57.62M |
| 1-day change | +4.38% | -3.84% |
| YTD return | -68.77% | -10.02% |
| 1-year return | -51.61% | -80.86% |
| 5-year return | -94.87% | -82.79% |
| EPS (TTM) | $-1.19 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.82 | $2.37 |
| 52-week low | $0.85 | $0.20 |
| Distance from 52-week high | -75.93% | -84.78% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +539.62% | +443.24% |
| Average volume | 3.81M | 4.04M |
| Shares outstanding | 62.97M | 159.69M |
| Employees | 64 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CNTB has outperformed MREO by 29.2 percentage points over the past year.
About Connect Biopharma
CNTB stock →Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Health Care · Biotechnology: Pharmaceutical Preparations · 64 employees
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
CNTB vs MREO FAQ
Which is bigger, Connect Biopharma or Mereo BioPharma Group?
Connect Biopharma (CNTB) is larger, with a market capitalization of $57.89M compared with $57.62M for Mereo BioPharma Group (MREO).
Which stock has performed better over the past year, CNTB or MREO?
CNTB returned -51.61% over the past 12 months, compared with -80.86% for MREO (price return, excluding dividends). Past performance does not predict future results.
Are Connect Biopharma and Mereo BioPharma Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.